No Data
No Data
Express News | Shanghai Junshi Biosciences - Js125 Received Acceptance Notice for Investigational New Drug Application by Nmpa
Junshi Bio (688180.SH): JS125 has received a letter of clinical trial application acceptance notice for drugs.
On July 9th, Gelunhui reported that Junshi Bio (688180.SH) received a "Notice of Acceptance" issued by the National Medical Products Administration regarding the clinical trial application of WJ47156 tablets (project code"JS125"). JS125 is a histone deacetylase inhibitor (HDACs) inhibitor jointly developed by the company and Microcore Biotech (Shanghai) Co., Ltd., intended for the treatment of malignant tumors and belongs to the class of epigenetic regulatory drug.
Hong Kong stocks are fluctuating. Biomedical stocks have all fallen back due to the policy of innovative drug bullishness. Institutions say that negotiating difficulty has increased in the new environment.
Biomedical stocks fell across the board. As of press time, Remegen (09995) fell 20.18% to HKD 17.24, Tigermed (03347) fell 6.59% to HKD 26.95, Wuxi AppTec (02359) fell 3.95% to HKD 27.95, and Junshi Bio (01877) fell 2.25% to HKD 12.18.
Junshi Bio (01877) has repurchased 34,4000 A-shares in June.
Junshi Bio (01877) announced that in June 2024, the company will complete the trade through the trading system of Shanghai Exchange to ...
Junshi Biosciences (688180.SH): Has repurchased 0.0828% of the shares.
Junshi Bio (688180.SH) announced that as of June 30, 2024, the company has repurchased 815,871 shares through the Shanghai Stock Exchange trading system via centralized bidding trading, accounting for 0.0828% of the total share capital. The highest repurchase price was CNY 41.69 per share, the lowest price was CNY 29.03 per share, and the total amount paid was CNY 30,883,207.73 (excluding transaction fees such as stamp duty and commission).
Strong Week for Shanghai Junshi Biosciences (HKG:1877) Shareholders Doesn't Alleviate Pain of Three-year Loss
While not a mind-blowing move, it is good to see that the Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) share price has gained 19% in the last three months. But that is meagre solace in the face
No Data